Last updated: 2026-09-16 09:45:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Krystal Biotech, Inc. (KRYS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $336.60, with a market capitalisation of $10.06B and a P/E ratio of 41.27. Over the past 52 weeks, its price has ranged from $151.88 to $382.54. This page covers its latest market performance, valuation, price trends and company information.
$10.06B | |
$336.60 | |
$382.54 | |
$8.03 | |
$336.68 | |
2.00 | |
403.31K | |
41.27 | |
$382.54 | |
$151.88 | |
-- | |
-- |
Krystal Biotech, Inc. (KRYS) is trading at $336.60 in pre-market trading as of 2026-09-16 08:33:00, down 0.03% ($0.08) from the previous close of $336.68
Pre-market trading shows how investors are pricing KRYS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Krystal Biotech, Inc. (KRYS) moved from $358.24 to $336.60, representing a decline of 6.04% ($21.64).
The stock traded between $331.79 and $371.99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 242.54 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 80.1%
KRYS is currently trading at $336.60, placing it 80.1% of the way from its 52-week low of $151.88 to its 52-week high of $382.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 295 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Krystal Biotech, Inc. (KRYS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.